United States Food & Drug Administration (USFDA) has completed the surveillance inspection of Suven Pharmaceuticals’ Wholly Owned Subsidiary -- Casper Pharma. The inspection took place from July 8, 2024, to July 12, 2024. Following the inspection, USFDA issued a Form 483 with two observations, which are procedural in nature.
Suven Pharmaceuticals is a bio-pharmaceutical company, incorporated with the object of being engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
